Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An italian lung cancer task force (FONICAP) phase II study

Abstract

Since DMPM has a long latency period, the overall DMPM incidence is still increasing despite recent legis-

A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma

“…Median survival times of patients treated with cisplatin and doxorubicin ranged from 8.8 to 15 months [15][16][17][18][19][20][21], with median survival of more than 1 year in only three studies [16,18,21] (Table 4). So, the median survival time of our patients treated with cisplatin and epirubicin appears at least equivalent.…”

“…We could compare the toxicity profile of cisplatin-doxorubicin containing regimens [15][16][17][18][19][20][21] with that of cisplatin plus epirubicin (Table 4), allowing some indirect assessment of quality of life. This analysis was limited by missing data in the articles previously published.…”

Chemotherapy for malignant pleural mesothelioma: past results and recent developments

“…Initially encouraging response rates experienced with the doxorubicincisplatin combination in two phase II studies carried out in Germany (RR: 46%) and Italy (RR: 25%) (Henss et al, 1988;Ardizzoni et al, 1991) failed to be confirmed by a subsequent, randomised CALGB study of doxorubicin -cisplatin vs mitomycin -cisplatin treatment (Chahinian et al, 1993). The doxorubicin-cisplatin doublet was only able to produce a 14% response rate and proved inferior to the mitomycin -cisplatin combination (RR: 26%).…”

Sequential chemotherapy with cisplatin/gemcitabine (CG) followed by mitoxantrone/methotrexate/mitomycin (MMM) in patients with malignant pleural mesothelioma

“…Some combination regimens have been reported as inducing higher response rates in small phase II trials. Among the combination chemotherapy regimens, doxorubicin-cisplatin doublets have been the most used drugs in phase II studies [32,33]. Most recently, oxaliplatincontaining combinations have shown activity in phase II studies: the ORR was 20% in the oxaliplatin and raltitrexed combination [34], 23% in the oxaliplatin and vinorelbine combination [35] and 40% in the oxaliplatin and gemcitabine combination [36].…”